15 Surprising Symptoms That Can Be Early Warning Signs of Cancer

USPSTF Upgrades PSA Test Recommendation For Prostate Cancer Screening

DENVER, May 8, 2018 /PRNewswire/ -- The Prostate Conditions Education Council (PCEC), a national organization committed to men's health and a leader in prostate cancer early detection, supports the updated recommendation from the U.S. Preventive Services Task Force (USPSTF) upgrading prostate-specific antigen (PSA) screening to a "C" rating for prostate cancer testing for men ages 55-69.

The recommendation released today by the USPSTF signifies a shift in guidance aligning with recent data in support of PSA screening. An analysis published in Annals of Internal Medicine found that PSA screening lowered the risk for prostate cancer death by 25 to 32 percent when compared with those who were not screened.

"This update is a win for early detection of prostate cancer. It's not about more testing – it's about screening smarter and identifying disease at the earliest possible stage," said Alan W. Partin, M.D., Ph.D., PCEC council member and chairman of the Department of Urology at Johns Hopkins. "Prostate cancer is nearly 100 percent survivable if caught early and screening is the best way to do that."

The PCEC recommends a baseline prostate health assessment for all men beginning at age 40 to determine risk stratification, and follow-up or monitoring based on those results or specific risk populations. The organization has been a steadfast proponent of screening for early detection that is not solely limited to the PSA test and provides education on other screening methods, genomic testing and prostate cancer biomarkers that help individualize patient care and treatment choices.

"Throughout the years, we've continued to stand by evidence-based information to raise awareness and equip patients and providers for decision-making around prostate health," said Wendy Poage, president of the PCEC. "There's more work to be done to ensure men and their loved ones understand their risk and take action for their health, but these updates to the recommendation for PSA screening are a positive step in the right direction."

About the Prostate Conditions Education CouncilA national organization committed to men's health, the PCEC is the nation's leading resource for information on prostate health. The PCEC is dedicated to saving lives through awareness and the education of men, the women in their lives and the medical community about prostate cancer prevalence, the importance of early detection and available treatment options, as well as other men's health issues.

The Council, comprised of a consortium of leading physicians, health educators, scientists and prostate cancer advocates, aims to conduct nationwide screenings for men and perform research that will aid in the detection and treatment of prostate conditions. More information is available at prostateconditions.Org.

 

View original content with multimedia:http://www.Prnewswire.Com/news-releases/uspstf-upgrades-psa-test-recommendation-for-prostate-cancer-screening-300644983.Html

SOURCE Prostate Conditions Education Council

PSA Testing Rates Rose After USPSTF Revised Prostate Cancer ... - Healio

February 01, 2022

3 min read

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.

Back to Healio

PSA testing rates increased after the U.S. Preventive Services Task Force revised its guidance on prostate cancer screening in 2017, according to results of a large national cohort study in JAMA Oncology.

The task force issued guidance in 2012 advising against PSA testing for all men. The panel later reversed its guidance, endorsing individual decision-making for men aged 55 to 69 years. It does not have a recommendation on PSA testing for men aged younger than 55 years but recommended against such screening for men aged 70 years or older.

Source: Adobe Stock.

Since the guidance revision, PSA testing increased among men in all age groups, results showed.

Michael S. Leapman

"A strong motivator for this study comes from my clinical practice as a urologist, where patients often express deep interest in having consistent and straightforward recommendations about screening tests that can reduce their risks for prostate cancer," Michael S. Leapman, MD, assistant professor of urology and clinical program leader in the prostate and urologic cancers program at Yale Cancer Center, told Healio. "Many patients and doctors are also bewildered by the controversies and major shifts in guidance that have occurred for PSA testing within the past decade. By studying changes in national PSA testing practices, we hope to provide greater clarity about current patterns of care, as well as the effects of major shifts in clinical guidelines."

Leapman and colleagues analyzed de-identified claims data from Blue Cross Blue Shield beneficiaries aged 40 to 89 years (median age, 53 years; interquartile range, 47-59) from Jan. 1, 2013, through Dec. 31, 2019. A median 8.08 million beneficiaries were eligible for in each bimonthly period.

Leapman and colleagues calculated age-adjusted rates of PSA testing in bimonthly periods and compared PSA testing rates from calendar years before and after the guideline change (January to December 2016 vs. January to December 2019).

They also used interrupted time series analyses to evaluate the association of both the draft (April 2017) and published (May 2018) US Preventive Services Task Force (USPSTF) guidelines with rate of PSA testing.

Researchers further evaluated changes in PSA testing rates among beneficiaries within the age categories used in the guidelines: 40-54 years, 55-69 years and 70-89 years.

They aimed to determine whether the reversal of the USPSTF guideline advising against PSA testing had any association with utilization rates.

Results showed a relative increase of 12.5% (95% CI, 1.1-24.4) in rates of PSA testing among men aged 40 to 89 years during the study period, from a mean 32.5 tests per 100 person-years to 36.5 tests per 100 person-years.

In the same time period, mean rates of PSA increased from 20.6 to 22.7 tests per 100 person-years among men aged 40 to 54 years, equating to a relative increase of 10.1% (95% CI, –2.8 to 23.7); 49.8 to 55.8 tests per 100 person-years among men aged 55 to 69 years, equating to a relative increase of 12.1% (95% CI, – 0.2% to 25.2%); and 38 to 44.2 tests per 100 person-years among men aged 70 to 89 years, equating to a relative increase of 16.2% (95% CI, 4.2-29).

Interrupted time series analysis revealed a significant increase in PSA testing after April 2017 among all beneficiaries (0.3 tests per 100 person-years for each bimonthly period; P < .001).

"We were intrigued by the findings," Leapman said. "Uncovering increasing use of PSA testing overall may be seen as an expected finding in light of renewed support from the guideline. However, findings of increased testing in patient groups for whom screening remains discouraged — particularly patients aged older than 70 years — raises questions about the specificity with which the change in guidelines has been implemented."

Study limitations included that its most recent data did not take into account the likely significant effects of the COVID-19 pandemic on rates of cancer screening and PSA testing. Additionally, although the 2018 guideline noted Black men face higher risk for prostate cancer, the USPSTF did not make specific recommendations by race. Additional research is needed to examine PSA testing difference by race or other sociodemographic factors, researchers concluded.

"We are also interested in understanding downstream effects of these changes, such as differences in use of prostate biopsy, cancer diagnosis, treatment and outcome," Leapman said.

For more information:

Michael S. Leapman, MD, can be reached at Department of Urology, Yale University School of Medicine, 310 Cedar St., BML 238C, New Haven CT, 06520; email: michael.Leapman@yale.Edu.

Back to Top Kevin Ginsburg, MD Leapman and colleagues reported that after publication of the 2018 USPSTF prostate cancer screening recommendations, the rate of PSA testing rose from 32.5 to 36.5 tests per 100 person-years. This can be thought of as an additional four PSA tests being ordered among a group of 100 men for each year these men received insurance from Blue Cross Blue Shield. Importantly, the authors noted an increase in PSA testing (to various degrees) among men of all age groups, including men for whom prostate cancer screening typically is not recommended. The 2018 recommendations were an important step to reverse some of the potential harms associated with de-emphasizing and recommending against prostate cancer screening for age-appropriate men. As many providers who treat prostate cancer know, PSA screening has played an integral role in reducing death due to prostate cancer, as well as limiting morbidity from the development of metastatic disease. The authors show the importance of national recommendations and guidelines on medical decision-making and screening, and the potential implications of these guideline statements on physicians' behavior. As we continue to emphasize prostate cancer screening for men who are most likely to benefit from the diagnosis and treatment of clinically significant disease, we must use PSA screening wisely and appropriately to maximize the tremendous benefit derived from screening appropriate men while minimizing potential harms from inappropriate screening. Kevin Ginsburg, MD Fox Chase Cancer Center

Disclosures: Ginsburg reports no relevant financial disclosures.

Sources/DisclosuresCollapse Disclosures: Leapman reports grants from NIH/NCI. Please see the study for all other authors' financial disclosures.

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on . Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.Com.

Back to Healio

USPSTF Recommendation Did Not Impact PSA Testing Referrals, Study Finds

A study published in the journal Cancer has discovered that a 2012 recommendation for prostate cancer screening did not change physician behavior.

A study published in the journal Cancer has evaluated real-world data on prescribing patterns of physicians and clinical practices following a 2012 guideline change by the US Preventive Services Task Force (USPSTF) for prostate-specific antigen (PSA) testing. USPSTF gave a D rating to PSA testing for screening for prostate cancer, saying the harms outweighed benefits. The current study has found that the recommendation did not significantly change physician behavior.

 

The authors analyzed PSA orders and urology referrals from a tertiary referral center in the southern United States. The order was classified as a screening test if ordered by physicians who had an appointment in internal medicine, family medicine, or general internal medicine.

 

Over a 5-year period between January 2010 and July 2015, 63,722 PSA orders were made, of which 54,684 could be evaluated. These were a part of 275,784 unique ambulatory visits that were documented. Primary care providers (PCPs), the study found, ordered 17,315 PSA tests and 858 urology referrals. The PSA value at the time of referral was significantly higher (P = .022). However, the number of PSA tests per ambulatory visit, the number of referrals per ambulatory visit, the age at the time of the urology referral, and the proportion of PSA tests performed outside the recommended age range did not significantly change.

 

Based on their results the authors conclude that there was no significant impact on physician referral behavior post the USPSTF recommendation.

 

This data contrasts a similar study published earlier this year in JAMA Internal Medicine, where the authors gathered data from the National Ambulatory Medical Care Survey to examine continued adoption of PSA testing and found more than a 50% drop in preventive PCP visits, from 36.5% in 2010 to 16.4% in 2012, and just a slight drop in urologist visits. The difference in outcomes might be the result of a difference in the demographics and even the study duration following the recommendation.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

---